Verseon’s groundbreaking drug discovery platform was featured in Nano Magazine’s article on whether AI can fundamentally change drug discovery.
Fremont, United States - December 21, 2021 /PressCable/ —
Fremont, CA – Verseon’s groundbreaking drug discovery platform was featured in Nano Magazine’s article on whether AI can fundamentally change drug discovery.
Nano Magazine concluded that although Verseon has built and used its own AI tools for parts of its drug development long before AI was a trendy buzzword, it has avoided the AI “hype-fest.” With its unique approach that combines physics-based molecular modeling and AI, Verseon’s platform changes how completely new drugs can be discovered. Whereas other players in AI-driven pharmaceutical development can only find small variations on existing compounds, Verseon’s platform drives pharmaceutical innovation with rapid, systematic development of multiple previously unexplored, chemically diverse candidates for each of its drug programs, which Nano Magazine called “a feat unheard of in the pharmaceutical industry.”
Pfizer’s former SVP of R&D Strategy and Verseon advisor Robert Karr said, “Everyone else has merely dabbled in the field of systematic drug discovery. Verseon’s disruptive platform changes how drugs can be discovered and developed, and the company is poised to make a dramatic impact on modern medicine.”
Verseon currently has 14 drug candidates spanning 7 programs in the areas of cardiovascular disease, diabetes, cancer, and liver disease in various stages of development and clinical testing.
Verseon’s anticoagulant program is currently in Phase 1 clinical trials. This drug (VE-1902) promises to change the standard of care for tens of millions of patients at risk for stroke and heart attack. Ideal treatment for these patients would be long-term combination therapy with antiplatelet and anticoagulant drugs, but this treatment protocol poses significant risk of major bleeding events. Verseon’s Precision Oral Anticoagulants (PROACs) promise to significantly reduce the risk of major bleeding and would make long-term combination therapy a safe and viable treatment.
UCL Professor of Cardiology John Deanfield remarked: “Verseon’s platelet-sparing anticoagulants with their unique mode of action and low bleeding risk look very promising. Their drugs represent an exciting ‘precision medicine’ opportunity for the treatment of a large population of cardiovascular disease patients.”
About Verseon
To advance global health, Verseon International Corporation (www.verseon.com) has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company’s drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and advanced AI to develop drug compounds that have never before been synthesized—and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.
Contact Info:
Name: Walter Jones
Email: Send Email
Organization: Verseon
Address: 47000 Warm Springs Boulevard, Fremont, CA 94539, United States
Website: https://www.verseon.com
Source: PressCable
Release ID: 89057403
